113 related articles for article (PubMed ID: 2440513)
1. Brain neuropeptides in progressive supranuclear palsy.
Taquet H; Javoy-Agid F; Mauborgne A; Benoliel JJ; Agid Y; Legrand JC; Hamon M; Cesselin F
Brain Res; 1987 May; 411(1):178-82. PubMed ID: 2440513
[TBL] [Abstract][Full Text] [Related]
2. Effects of a unilateral 6-hydroxydopamine lesion and prolonged L-3,4-dihydroxyphenylalanine treatment on peptidergic systems in rat basal ganglia.
Taylor MD; De Ceballos ML; Rose S; Jenner P; Marsden CD
Eur J Pharmacol; 1992 Aug; 219(2):183-92. PubMed ID: 1385171
[TBL] [Abstract][Full Text] [Related]
3. Levels of Met-enkephalin, Leu-enkephalin, substance P and cholecystokinin in the brain of the common marmoset following long term 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine treatment.
Taquet H; Nomoto M; Rose S; Jenner P; Javoy-Agid F; Mauborgne A; Benoliel JJ; Marsden CD; Legrand JC; Agid Y
Neuropeptides; 1988 Oct; 12(3):105-10. PubMed ID: 2468106
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical study of the striatal efferents and nigral dopaminergic neurons in parkinsonism-dementia complex on Guam in comparison with those in Parkinson's and Alzheimer's diseases.
Goto S; Hirano A; Matsumoto S
Ann Neurol; 1990 May; 27(5):520-7. PubMed ID: 1694418
[TBL] [Abstract][Full Text] [Related]
5. Brain monoamines in progressive supranuclear palsy--comparison with idiopathic Parkinson's disease.
Hornykiewicz O; Shannak K
J Neural Transm Suppl; 1994; 42():219-27. PubMed ID: 7964689
[TBL] [Abstract][Full Text] [Related]
6. Alterations in peptide levels in Parkinson's disease and incidental Lewy body disease.
Fernandez A; de Ceballos ML; Rose S; Jenner P; Marsden CD
Brain; 1996 Jun; 119 ( Pt 3)():823-30. PubMed ID: 8673494
[TBL] [Abstract][Full Text] [Related]
7. Immunocytochemical studies of substance P and leucine-enkephalin in Huntington's disease.
Marshall PE; Landis DM; Zalneraitis EL
Brain Res; 1983 Dec; 289(1-2):11-26. PubMed ID: 6198034
[TBL] [Abstract][Full Text] [Related]
8. Striatal neuropeptide levels in Parkinson's disease patients.
Fernandez A; de Ceballos ML; Jenner P; Marsden CD
Neurosci Lett; 1992 Oct; 145(2):171-4. PubMed ID: 1281532
[TBL] [Abstract][Full Text] [Related]
9. Brain enkephalin receptors in Parkinson's disease.
Rinne UK; Rinne JK; Rinne JO; Laakso K; Tenovuo O; Lönnberg P; Koskinen V
J Neural Transm Suppl; 1983; 19():163-71. PubMed ID: 6321647
[TBL] [Abstract][Full Text] [Related]
10. Excessive dopamine neuron loss in progressive supranuclear palsy.
Murphy KE; Karaconji T; Hardman CD; Halliday GM
Mov Disord; 2008 Mar; 23(4):607-10. PubMed ID: 18163454
[TBL] [Abstract][Full Text] [Related]
11. Progressive supranuclear palsy affects both the substantia nigra pars compacta and reticulata.
Hardman CD; Halliday GM; McRitchie DA; Cartwright HR; Morris JG
Exp Neurol; 1997 Mar; 144(1):183-92. PubMed ID: 9126169
[TBL] [Abstract][Full Text] [Related]
12. Free-water imaging in Parkinson's disease and atypical parkinsonism.
Planetta PJ; Ofori E; Pasternak O; Burciu RG; Shukla P; DeSimone JC; Okun MS; McFarland NR; Vaillancourt DE
Brain; 2016 Feb; 139(Pt 2):495-508. PubMed ID: 26705348
[TBL] [Abstract][Full Text] [Related]
13. Regulation of dopamine receptor and neuropeptide expression in the basal ganglia of monkeys treated with MPTP.
Betarbet R; Greenamyre JT
Exp Neurol; 2004 Oct; 189(2):393-403. PubMed ID: 15380489
[TBL] [Abstract][Full Text] [Related]
14. Neuropeptide levels in the basal ganglia of aged common marmosets following prolonged treatment with MPTP.
Taylor MD; de Ceballos ML; Rose S; Chong PN; Jenner P; Marsden CD
J Neural Transm Park Dis Dement Sect; 1991; 3(2):99-108. PubMed ID: 1716907
[TBL] [Abstract][Full Text] [Related]
15. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis.
Hirsch EC; Brandel JP; Galle P; Javoy-Agid F; Agid Y
J Neurochem; 1991 Feb; 56(2):446-51. PubMed ID: 1988548
[TBL] [Abstract][Full Text] [Related]
16. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy.
Brücke T; Asenbaum S; Pirker W; Djamshidian S; Wenger S; Wöber C; Müller C; Podreka I
J Neural Transm Suppl; 1997; 50():9-24. PubMed ID: 9120429
[TBL] [Abstract][Full Text] [Related]
17. Lesion of the dorsorostral midbrain sparing the nigrostriatal tract mimics axial rigidity seen in progressive supranuclear palsy.
Lewerenz J; Zurowski B; Jenicke L; Bäumer T; Lees AJ; Münchau A
Mov Disord; 2005 Aug; 20(8):1071-5. PubMed ID: 15838851
[TBL] [Abstract][Full Text] [Related]
18. Loss of thalamic intralaminar nuclei in progressive supranuclear palsy and Parkinson's disease: clinical and therapeutic implications.
Henderson JM; Carpenter K; Cartwright H; Halliday GM
Brain; 2000 Jul; 123 ( Pt 7)():1410-21. PubMed ID: 10869053
[TBL] [Abstract][Full Text] [Related]
19. An immunohistochemical study of six biologically active peptides in the human brain.
Bouras C; Magistretti PJ; Morrison JH
Hum Neurobiol; 1986; 5(4):213-26. PubMed ID: 2434454
[TBL] [Abstract][Full Text] [Related]
20. Alterations of neurotransmitter receptors and neurotransmitter transporters in progressive supranuclear palsy.
Landwehrmeyer B; Palacios JM
J Neural Transm Suppl; 1994; 42():229-46. PubMed ID: 7525868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
